摘要:
The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.
摘要:
The invention describes an improved method for making monosialoganglioside GM3 and its intermediates. Following reaction of a neuraminic acid donor and a lactose acceptor in the presence of an acid catalyst, the .alpha. and .beta. isomers of GM3 are formed. The .alpha. isomer is converted to a lactone, via action of a ring forming basic catalyst, which is then separable from the .beta. isomer. The lactone is then treated with a basic catalyst in the presence of an alcohol, to form GM3 or a GM3 intermediate.
摘要:
Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G.sub.D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G.sub.D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab').sub.2 fragments) reacting with G.sub.D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G.sub.D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.
摘要:
Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.
摘要:
Human TNF(LuKII) having a specific activity of at least 1.5.times.10.sup.5 units per milligram of total protein is produced by contacting a TNF-containing protein composition, which has been harvested from human cell lines of hematopoietic origin or recombinant origin, in separate adsorption stages with glass beads, lentil lectin bound to Sepharose, and procion red agarose, thereby selectively to adsorb TNF in each stage, while leaving some impurities unadsorbed, each contact stage being followed by contact of the adsorbent with an eluant thereby to obtain a solution of more highly purified TNF after each stage. The purified human TNF(LuKII) is used to produce monoclonal antibodies against TNF(LuKII) and such antibodies can be used to assay samples for the presence of TNF(LuKII).
摘要:
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
摘要:
The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers.
摘要:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
摘要:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
摘要:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.